Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Cenicriviroc (formerly TBR-652)
Also known as: formerly TAK-652
print preview
bookmark
share with colleague
General Information
Company
Takeda Pharmaceutical Co. Ltd.
Description
Dual CC chemokine receptor 5 (CCR5) and CCR2 antagonist
Molecular Target
CC chemokine receptor 5 (CCR5) (CD195)
;
CC chemokine receptor 2 (CCR2) (CD192)
Mechanism of Action
CC chemokine receptor 2 (CCR2) antagonist; CC chemokine receptor 5 (CCR5) antagonist
Latest Stage of Development
Phase II
Indication
HIV / AIDS
Partner
Tobira Therapeutics Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy